Analyst consensus rating
Enanta Pharmaceuticals Analyst Rating: Strong Buy
ENTA is rated Strong Buy by 5 analysts with a $19.80 target. As of 2026-09-01.
Direct answer
Enanta Pharmaceuticals's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $19.80.
Forecast evidence checked September 1, 2026.
Get free Enanta Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.33
- Average price target
- $19.80
- High price target
- $20.00
- Low price target
- $19.00
- Low target gap
- +42.5%
- Target upside
- +48.5%
- High target gap
- +50%
- Target range width
- 7.5%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $19.80.
How far are Enanta Pharmaceuticals's low and high targets from the recorded price?
The low target implies +42.5%, while the high target implies +50%.
How many analysts are included in Enanta Pharmaceuticals's consensus?
The verified consensus includes 5 analysts.
How is Enanta Pharmaceuticals's target upside or downside calculated?
The average target of $19.80 is divided by the recorded price of $13.33, then one is subtracted to produce +48.5%. This does not guarantee a future return.
When was Enanta Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.